← ANALYST RATINGS · TIPRANKS

Enovis (ENOV): analyst forecast and price target

$19.59 +1.24% close 16.10.26 · market cap $1.1B · Healthcare · Medical - Devices IWM 0.04%
Price targets and ratings of

Analyst consensus

Strong Buy

10 Buy1 Hold0 Sell

Ratings of 11 analysts in the last 3 months

12-month forecast

$36.20+84.8% upside

Based on 11 price targets given in the last 3 months, the average target is $36.20, the highest $47.00, the lowest $27.00. The average is +84.8% from the last price of $19.59.

$20.00$30.00$40.00Jan 26AprJulOctJan 27AprJulOctHigh$47.00Average$36.20Low$27.00
Highest target $47.00 Average target $36.20 Lowest target $27.00
AnalystFirmPrice target RatingUpsideAction Date Move vs SPY
Michael Matson★★★★★★★★★★#1853 · hits 50% · avg +6.0% Needham $52.00 → $34.00−34.6% Buy +73.6% Reiterated 12.10.26on TipRanks 07:20 +3.2%next day +4.1%
Patrick Wood★★★★★★★★★★#10768 · hits 50% · avg −2.1% UBS $51.00 → $44.00−13.7% Buy +124.6% Reiterated 05.10.26on TipRanks 09:16 +4.5%next day −3.2% · 5 days −2.8%
Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% BTIG $36.00 Buy +83.8% Reiterated 02.10.26on TipRanks Oct 12 09:45 −2.3%next day +4.5% · 5 days −1.6%
Larry Biegelsen★★★★★★★★★★#2729 · hits 53% · avg +3.8% Wells Fargo $33.00 Buy +68.5% Reiterated 08.09.26on TipRanks Sep 9 06:20 +8.2%next day −4.3% · 5 days −9.1%
David Turkaly★★★★★★★★★★#11791 · hits 40% · avg −4.0% Citizens JMP $55.00 → $47.00−14.5% Buy +139.9% Reiterated 02.09.26on TipRanks 06:10 −2.1%next day −5.0% · 5 days −7.9%
Keith Hinton★★★★★★★★★★#7123 · hits 80% · avg +7.0% Freedom Capital Markets $41.00 → $36.00−12.2% Buy +83.8% Reiterated 01.09.26on TipRanks Sep 27 05:10 −15.8%next day −2.1% · 5 days −7.4%
Caitlin Roberts★★★★★★★★★★#1832 · hits 65% · avg +14.7% Canaccord Genuity $45.00 Buy +129.7% Reiterated 01.09.26on TipRanks Sep 2 06:55 −15.8%next day −2.1% · 5 days −7.4%
Vik Chopra★★★★★★★★★★#6076 · hits 45% · avg +1.9% BMO Capital $30.00 → $27.00−10.0% Buy +37.8% Assigned 01.09.26on TipRanks 14:00 −15.8%next day −2.1% · 5 days −7.4%
Steven Lichtman★★★★★★★★★★#568 · hits 54% · avg +14.7% William Blair — Buy — Reiterated 14.08.26on TipRanks 10:35 +1.8%next day −4.6% · 5 days +1.4%
Robbie Marcus★★★★★★★★★★#1974 · hits 51% · avg +6.5% J.P. Morgan $28.00 Hold +42.9% Reiterated 10.08.26on TipRanks Aug 11 08:07 −8.9%next day +1.8% · 5 days +2.1%
Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% Evercore ISI $32.00 Buy +63.3% Reiterated 07.08.26on TipRanks 08:45 +0.5%next day −8.9% · 5 days −2.5%
Rong Li★★★★★★★★★★#8516 · hits 50% · avg +3.7% Jefferies $40.00 Buy +104.2% Reiterated 14.07.26on TipRanks Jul 21 21:03 −6.5%next day +3.4% · 5 days +10.4%
Jeff Johnson★★★★★★★★★★#1125 · hits 51% · avg +10.4% Robert W. Baird $45.00 → $37.00−17.8% Buy +88.9% Reiterated 08.05.26on TipRanks 08:55 −3.5%next day −6.8% · 5 days −8.6%

The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included

Best analysts covering Enovis

TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.

Most accurate

3 months Jeff Johnson★★★★★★★★★★Robert W. Baird · #1125
Hits 51%197 of 385 Average return +10.4%
1 year Vijay Kumar★★★★★★★★★★Evercore ISI · #2375
Hits 54%204 of 376 Average return +4.8%
2 years Vijay Kumar★★★★★★★★★★Evercore ISI · #2375
Hits 54%204 of 376 Average return +4.8%

Most profitable

3 months Jeff Johnson★★★★★★★★★★Robert W. Baird · #1125
Hits 51%197 of 385 Average return +10.4%
1 year Jeff Johnson★★★★★★★★★★Robert W. Baird · #1125
Hits 51%197 of 385 Average return +10.4%
2 years Vijay Kumar★★★★★★★★★★Evercore ISI · #2375
Hits 54%204 of 376 Average return +4.8%

How the average price target moved

The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $38.82 at a price of $18.27 (+112.5%); now: $36.20 at $19.59 (+84.8%).

$20.00$30.00$40.00Sep 15Oct 1Oct 15Top analysts$31.75Average target$36.20Price$19.59

PriceAverage targetTop analysts’ target

Recommendation trend

01020731Oct 2543Nov63Dec86Jan 2684Feb84Mar81Apr104May94Jun95Jul771Aug1381Sep1361Oct

Strong BuyBuyHoldSell

Rating05.2606.2607.2608.2609.2610.26
Strong Buy109971313
Buy445786
Hold000111
Sell000000

Earnings and sales forecast

Next report: 05.11.26 (Q3 2026, date not confirmed)

Earnings per share

Next quarter’s EPS estimate — $0.77 (from $0.71 to $0.83). Last quarter: $0.90.

Sales

Next quarter’s sales estimate — $557M (from $552M to $563M). Last quarter: $583M.

Best top-analyst consensus in the sector · Healthcare

AXGNAxoGen
MDWDMediwound
OCULOcular Therapeutix
OVIDOvid Therapeutics
ZYMEZymeworks
About Enovis
  • CEO: Damien McDonald
  • Employees: 7,802
  • 2711 Centerville Road, Wilmington, DE, 19808, US
  • www.enovis.com

Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.

Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗